Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

249 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Campbell CM, LoRusso S, Dispenzieri A, Kristen AV, Maurer MS, Rapezzi C, Lairez O, Drachman B, Garcia-Pavia P, Grogan M, Chapman D, Amass L; THAOS investigators. Campbell CM, et al. Among authors: lairez o. Cardiol Ther. 2022 Sep;11(3):393-405. doi: 10.1007/s40119-022-00265-7. Epub 2022 May 18. Cardiol Ther. 2022. PMID: 35583798 Free PMC article.
Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey.
Nativi-Nicolau J, Siu A, Dispenzieri A, Maurer MS, Rapezzi C, Kristen AV, Garcia-Pavia P, LoRusso S, Waddington-Cruz M, Lairez O, Witteles R, Chapman D, Amass L, Grogan M; THAOS Investigators. Nativi-Nicolau J, et al. Among authors: lairez o. JACC CardioOncol. 2021 Oct 19;3(4):537-546. doi: 10.1016/j.jaccao.2021.08.009. eCollection 2021 Oct. JACC CardioOncol. 2021. PMID: 34729526 Free PMC article.
Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update.
Dispenzieri A, Coelho T, Conceição I, Waddington-Cruz M, Wixner J, Kristen AV, Rapezzi C, Planté-Bordeneuve V, Gonzalez-Moreno J, Maurer MS, Grogan M, Chapman D, Amass L; THAOS investigators. Dispenzieri A, et al. Orphanet J Rare Dis. 2022 Jun 18;17(1):236. doi: 10.1186/s13023-022-02359-w. Orphanet J Rare Dis. 2022. PMID: 35717381 Free PMC article.
Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid.
Garcia-Pavia P, Aus dem Siepen F, Donal E, Lairez O, van der Meer P, Kristen AV, Mercuri MF, Michalon A, Frost RJA, Grimm J, Nitsch RM, Hock C, Kahr PC, Damy T. Garcia-Pavia P, et al. Among authors: lairez o. N Engl J Med. 2023 Jul 20;389(3):239-250. doi: 10.1056/NEJMoa2303765. Epub 2023 May 20. N Engl J Med. 2023. PMID: 37212440 Clinical Trial.
Pattern of myocardial 99mTc-HMDP uptake and impact on myocardial function in patients with transthyretin cardiac amyloidosis.
Pradel S, Brun S, Victor G, Pascal P, Fournier P, Ribes D, Lavie-Badie Y, Galinier M, Carrié D, Berry I, Lairez O; Toulouse Amyloidosis Research Network collaborators. Pradel S, et al. Among authors: lairez o. J Nucl Cardiol. 2020 Feb;27(1):96-105. doi: 10.1007/s12350-018-1316-6. Epub 2018 Jun 7. J Nucl Cardiol. 2020. PMID: 29881913
Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis.
Nicol M, Deney A, Lairez O, Vergaro G, Emdin M, Carecci A, Inamo J, Montfort A, Neviere R, Damy T, Harel S, Royer B, Baudet M, Cohen-Solal A, Arnulf B, Logeart D. Nicol M, et al. Among authors: lairez o. Eur J Heart Fail. 2021 Feb;23(2):231-239. doi: 10.1002/ejhf.2016. Epub 2020 Oct 22. Eur J Heart Fail. 2021. PMID: 33006180 Free article.
249 results